About lb pharmaceuticals inc - LBRX
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.
LBRX At a Glance
LB Pharmaceuticals, Inc.
One Pennsylvania Plaza
New York, New York 10119
| Phone | 1-212-605-0300 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -25,205,000.00 | |
| Sector | Health Technology | Employees | 27 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LBRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.869 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.026 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.013 |
LBRX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -933,518.519 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
LBRX Liquidity
| Current Ratio | 41.445 |
| Quick Ratio | 41.445 |
| Cash Ratio | 39.669 |
LBRX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -14.55 |
| Return on Equity | -15.703 |
| Return on Total Capital | -8.267 |
| Return on Invested Capital | -15.413 |
LBRX Capital Structure
| Total Debt to Total Equity | 1.184 |
| Total Debt to Total Capital | 1.171 |
| Total Debt to Total Assets | 1.14 |
| Long-Term Debt to Equity | 0.942 |
| Long-Term Debt to Total Capital | 0.931 |